181 related articles for article (PubMed ID: 24925055)
1. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma.
Riehle KJ; Yeh MM; Yu JJ; Kenerson HL; Harris WP; Park JO; Yeung RS
Mod Pathol; 2015 Jan; 28(1):103-10. PubMed ID: 24925055
[TBL] [Abstract][Full Text] [Related]
2. Akt and mTORC1 have different roles during liver tumorigenesis in mice.
Kenerson HL; Yeh MM; Kazami M; Jiang X; Riehle KJ; McIntyre RL; Park JO; Kwon S; Campbell JS; Yeung RS
Gastroenterology; 2013 May; 144(5):1055-65. PubMed ID: 23376645
[TBL] [Abstract][Full Text] [Related]
3. FGFR1 and FGFR2 in fibrolamellar carcinoma.
Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
[TBL] [Abstract][Full Text] [Related]
4. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
5. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
6. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma.
Patonai A; Erdélyi-Belle B; Korompay A; Somorácz A; Straub BK; Schirmacher P; Kovalszky I; Lotz G; Kiss A; Schaff Z
Virchows Arch; 2011 Jun; 458(6):679-88. PubMed ID: 21503766
[TBL] [Abstract][Full Text] [Related]
7. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Menon S; Yecies JL; Zhang HH; Howell JJ; Nicholatos J; Harputlugil E; Bronson RT; Kwiatkowski DJ; Manning BD
Sci Signal; 2012 Mar; 5(217):ra24. PubMed ID: 22457330
[TBL] [Abstract][Full Text] [Related]
8. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
[TBL] [Abstract][Full Text] [Related]
9. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L
Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789
[TBL] [Abstract][Full Text] [Related]
10. Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1A.
Xu BH; Li XX; Yang Y; Zhang MY; Rao HL; Wang HY; Zheng XF
Oncotarget; 2015 Aug; 6(25):20813-28. PubMed ID: 26308575
[TBL] [Abstract][Full Text] [Related]
11. Signaling by FGF Receptor 2, Not FGF Receptor 1, Regulates Myelin Thickness through Activation of ERK1/2-MAPK, Which Promotes mTORC1 Activity in an Akt-Independent Manner.
Furusho M; Ishii A; Bansal R
J Neurosci; 2017 Mar; 37(11):2931-2946. PubMed ID: 28193689
[TBL] [Abstract][Full Text] [Related]
12. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
13. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells.
Wan ZY; Tian JS; Tan HW; Chow AL; Sim AY; Ban KH; Long YC
Hepatology; 2016 Oct; 64(4):1289-301. PubMed ID: 27178107
[TBL] [Abstract][Full Text] [Related]
15. HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT.
Noh JH; Bae HJ; Eun JW; Shen Q; Park SJ; Kim HS; Nam B; Shin WC; Lee EK; Lee K; Jang JJ; Park WS; Lee JY; Nam SW
Cancer Res; 2014 Mar; 74(6):1728-38. PubMed ID: 24448241
[TBL] [Abstract][Full Text] [Related]
16. Fibrolamellar carcinomas are positive for CD68.
Ross HM; Daniel HD; Vivekanandan P; Kannangai R; Yeh MM; Wu TT; Makhlouf HR; Torbenson M
Mod Pathol; 2011 Mar; 24(3):390-5. PubMed ID: 21113139
[TBL] [Abstract][Full Text] [Related]
17. Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.
Roberts JL; He B; Erickson A; Moreau R
Biochim Biophys Acta; 2016 Mar; 1861(3):166-76. PubMed ID: 26680362
[TBL] [Abstract][Full Text] [Related]
18. OIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways.
Li H; Zhang J; Lee MJ; Yu GR; Han X; Kim DG
Oncotarget; 2017 Mar; 8(11):18129-18144. PubMed ID: 28184024
[TBL] [Abstract][Full Text] [Related]
19. Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21.
Cornu M; Oppliger W; Albert V; Robitaille AM; Trapani F; Quagliata L; Fuhrer T; Sauer U; Terracciano L; Hall MN
Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11592-9. PubMed ID: 25082895
[TBL] [Abstract][Full Text] [Related]
20. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.
Wang C; Cigliano A; Delogu S; Armbruster J; Dombrowski F; Evert M; Chen X; Calvisi DF
Cell Cycle; 2013 Jul; 12(13):1999-2010. PubMed ID: 23759595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
